Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Most patients with inflammatory bowel diseases (IBD) are offered conventional medical therapy, because emerging therapies for IBD are regulated by health-care jurisdiction and often limited to academic centres. This review distils current evidence to provide a pragmatic approach to conventional IBD therapy, including aminosalicylates, corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, infliximab and adalimumab. It addresses drug efficacy, safety and salient practice points for optimal and appropriate practice.

Original publication

DOI

10.3109/00365521.2014.968864

Type

Journal article

Journal

Scand J Gastroenterol

Publication Date

01/2015

Volume

50

Pages

90 - 112

Keywords

Crohn’s disease, inflammatory bowel disease, ulcerative colitis, Anti-Bacterial Agents, Anti-Inflammatory Agents, Antibodies, Monoclonal, Gastrointestinal Agents, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Practice Guidelines as Topic, Treatment Outcome